FindTrial
Sign In

A controlled, randomized trial of MRA monotherapy in patients with rheumatoid arthritis(RA)

A controlled, randomized trial of MRA monotherapy in patients with rheumatoid arthritis(RA)

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080220016
Enrollment
Unknown
Registered
2005-09-02
Start date
2005-09-02
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

investigational material(s) Generic name etc : MRA (tocilizumab) INN of investigational material : Therapeutic category code : 399 Agents affecting metabolism, n.e.c. Dosage and Administration for In

Sponsors

Chugai Pharmaceutical Co., Ltd.
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Inclusion criteria (1) Diagnosed as having RA, on the basis of the criteria stipulated by the American Conference on Rheumatism (ACR) in 1987. (2) At 20 years old

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Efficacy: the ability to inhibit progression of structural damage Safety: Frequency and severity of adverse events and adverse drug reactions—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026